Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton Jul 07, 2015 12:45pm

85 Views

Post# 23898990

RE:chinee market impact???

i forgot to add this in the post, as per bloomberge Hepa was trading at 47.500 yuan or whatever on June 12 and today it traded at 26.72 yuan or whatever and seems to be in a trading halt (which i assume is part of the commie gov't CTO on a lot of chinee stocks)..lots of issues it seems...and PS if deal actually goes through as per framework i expect a price rise for RVX

Bullboard Posts

HPQ Silicon updates shareholders on Fumed Silica Reactor developments